Updated to add Vivus obesity drug results.
MOUNTAIN VIEW, Calif. (
(VVUS - Get Report) has announced results from two pivotal studies of its obesity drug Qnexa, and the weight loss is impressive.
In the "Equip" study of 1,267 morbidly obese patients, the full dose of Qnexa produced a placebo-adjusted weight loss of 9.4%.
Sixty-seven percent of patients on full-dose Qnexa lost at least 5% of their body weight, compared with 17% of placebo patients.
In the "conquer" study enrolling 2,487 patients (this group included patients who were less obese than those in the Equip study and also included patients with type 2 diabetes) the placebo-adjusted weight loss for Qnexa was 8.6%.
Seventy percent of full-dose Qnexa patients lost at least 5% of their body weight, compared with 21% of placebo patients.
Low- and mid-doses of Qnexa also were tested with good but less robust weight-loss results.
Tolerability was good, with 59% of Qnexa patients completing the 56 weeks of the study.
The drug's safety profile also looks clean, at least according to the press release. No suicide attempts, no suicidality risk or behavior detected in the study. Depression and depressive behavior were low at 2% across the study.
The company also ran a safety study that demonstrated no heart-rate abnormalities in patients treated with Qnexa.
Going by the data in the press release alone, Vivus' Qnexa data looks strong and tops the weight-loss results already seen by competitors
(ARNA - Get Report)
(OREX - Get Report)
Opexa's Surge a Headscratcher
Sometimes I watch the intraday moves in a biotech stock and say WTF?!?!
And so it was Tuesday with
(OPXA - Get Report)
, a micro-cap drug stock that soared 270% to $5.66. At one point in the afternoon, the stock was up 350%. More than 57 million shares traded hands on a 9.5 million-share float.
The cause of the buying frenzy was a press release from the company claiming "additional favorable data" from a previously completed phase II study of Tovaxin, a personalized immunotherapy, or "vaccine" for patients with relapsing-remitting multiple sclerosis.
I'll admit to never hearing of Opexa before this weekend, but negative data from this same phase II study of Tovaxin caused the stock to plummet 91% (from $2.34 all the way down to 22 cents) on Sept. 19, 2008.
On Oct. 23, 2008, Opexa provided an update on the Tovaxin phase II study, citing a small subset of multiple sclerosis patients that appeared to benefit from treatment with the vaccine -- or so Opexa claimed. The day after Opexa made this announcement, the stock remained flat at 25 cents.
On November 10, 2008, Dr. Fred Lublin, a multiple sclerosis expert at Mount Sinai School of Medicine, called the Tovaxin data "remarkably unimpressive" at a panel discussion sponsored by the investment bank Rodman & Renshaw.
Opexa offered another update from this same Tovaxin study on March 5 of this year, and once again, the stock did nothing, closing at 28 cents.